Welcome to our dedicated page for Pavmed news (Ticker: PAVMZ), a resource for investors and traders seeking the latest updates and insights on Pavmed stock.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) generates frequent news as a diversified commercial-stage medical technology company active in medical devices, diagnostics, and digital health. This news page aggregates press releases, market announcements, and other coverage related to PAVmed’s common stock and its Series Z warrants trading under the symbol PAVMZ.
Company updates often focus on the performance and milestones of its subsidiaries, particularly Lucid Diagnostics Inc. and Veris Health Inc. Lucid Diagnostics regularly reports on EsoGuard Esophageal DNA Test volumes, related revenue, clinical evidence packages, and developments in commercial coverage and reimbursement. Veris Health news commonly addresses progress on the Veris Cancer Care Platform, pilot programs with cancer centers, financing activities, and advancement of its implantable physiological monitor.
Investors following PAVMZ-related news can also expect announcements on quarterly and annual financial results, non-GAAP performance measures, and business update conference calls and webcasts. PAVmed frequently issues releases detailing business updates for specific quarters, including comments from management on strategy, subsidiary performance, and capital structure.
Regulatory and listing developments are another recurring theme. News items have covered PAVmed’s efforts to regain or maintain compliance with Nasdaq listing standards, including stockholders’ equity and minimum bid price requirements, as well as actions such as debt restructuring and deconsolidation of Lucid Diagnostics.
By monitoring this news feed, readers can track how PAVmed’s medical device, diagnostics, and digital health activities evolve over time, how Lucid Diagnostics and Veris Health contribute to the overall business, and how capital markets and regulatory developments intersect with the PAVM and PAVMZ securities.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the appointment of Debbie White to its Board of Directors. White brings extensive experience from industries including healthcare and biopharmaceuticals, serving on the Audit and Compensation Committees. Chairman Lishan Aklog expressed optimism about her role in enhancing strategy and operations as the company expands. White has held significant positions in organizations like Interserve and Sodexo, contributing to her expertise in business leadership and international commercialization. This strategic addition is expected to support PAVmed's growth trajectory.
Summary not available.
PAVmed (Nasdaq: PAVM, PAVMZ) announced that its CEO, Lishan Aklog, will present a corporate update at the 20th Annual Needham Healthcare Conference on April 15, 2021, at 8:00 AM EDT. Interested parties can access the live webcast and subsequent replay via the Investor Relations section on PAVmed's website. PAVmed is a multi-product medical technology company focused on rapidly advancing innovative products through a unique business model. Its diversified product pipeline addresses significant clinical needs across various areas including GI health, minimally invasive interventions, and infusion therapy.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a corporate update presentation at the Inaugural Emerging Growth Virtual Conference on March 17-19, 2021, hosted by M Vest LLC and Maxim Group LLC. The conference will feature industry leaders discussing healthcare topics and include issuer presentations, fireside chats, and live Q&A sessions. PAVmed is focused on advancing innovative medical technology products while addressing unmet clinical needs across various health sectors. For participation details, visit M Vest's website.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced it has fully retired its outstanding convertible debt using $14.5 million from a recent common stock offering. This decision is significant as it eliminates a notable financial liability and may improve the company's balance sheet. PAVmed operates as a multi-product medical device company with a focus on innovation in various clinical areas. Their diverse pipeline encompasses products across GI health, minimally invasive interventions, infusion therapy, and emerging innovations.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that Dr. Lishan Aklog, the Company's Chairman and CEO, has been appointed to the Board of Directors of the Advanced Medical Technology Association (AdvaMed). This appointment highlights Dr. Aklog's leadership and experience in the medical technology field. AdvaMed is a leading trade association focused on advancing medical technology and improving healthcare. Dr. Aklog expressed honor at joining the Board during a transformative time for the industry, aiming to advocate for ethical standards and access to innovative medical technologies.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has successfully closed its underwritten public offering of approximately 9.8 million common shares, raising about $45 million in gross proceeds. The funds will primarily be used to repay outstanding debts, including convertible notes, with the remainder allocated for working capital and corporate purposes. The offering was facilitated by Cantor Fitzgerald & Co., with additional participation from Lake Street Capital Markets and Maxim Group. The underwriter also holds a 30-day option to purchase up to 1.5 million extra shares.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has announced a public offering of approximately 9.8 million shares, aiming to generate about $45 million in gross proceeds. The offering is set to close around February 25, 2021, pending customary conditions. Proceeds will be used primarily to repay outstanding debt and for working capital. Cantor Fitzgerald & Co. serves as the lead manager, with options for underwriters to purchase an additional 1.5 million shares. The offering is made under an effective SEC registration statement, with pricing based on the market's last reported price of $5.55 per share.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has initiated a public offering of its common stock, with a possible 30-day option for underwriters to purchase an additional 15% of the offering. The offering aims to repay the company's outstanding debt, including convertible notes, and fund working capital. The offering is conducted under a shelf registration statement effective since September 17, 2020, with Cantor Fitzgerald & Co. as the sole book-running manager. The final terms will be disclosed in a subsequent prospectus supplement.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a strategic spin-off of its subsidiary Lucid Diagnostics, aiming to enhance its commercial potential through an IPO or SPAC merger. This decision follows a robust financial position bolstered by raising over $30 million, which supports Lucid's new multi-channel commercialization initiative for the EsoGuard Esophageal DNA Test. Key highlights include a strengthened sales team and a rebound in EsoGuard testing volume, although challenges remain with ongoing clinical studies and insurance coverage determinations.